


Accepted Manuscript

Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status

Mustafa N. Yenerel, Petra Muus, Amanda Wilson, Jeff Szer



PII: S1079-9796(17)30038-4

DOI: doi: [10.1016/j.bcnd.2017.03.013](https://doi.org/10.1016/j.bcnd.2017.03.013)

Reference: YBCMD 2176

To appear in: *Blood Cells, Molecules and Diseases*

Received date: 23 January 2017

Revised date: 22 March 2017

Accepted date: 25 March 2017

Please cite this article as: Mustafa N. Yenerel, Petra Muus, Amanda Wilson, Jeff Szer , Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ybcmd(2017), doi: [10.1016/j.bcnd.2017.03.013](https://doi.org/10.1016/j.bcnd.2017.03.013)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinical Course and Disease Burden in Patients with Paroxysmal Nocturnal Hemoglobinuria by Hemolytic Status

Mustafa N. Yenerel¹, Petra Muus², Amanda Wilson³, and Jeff Szer⁴

¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey (mnyenerel@gmail.com); ²Department of Hematology, Radboudumc, Nijmegen, The Netherlands (p.muus@kpnplanet.nl);

³Alexion Pharma International, Cambridge, Massachusetts, USA

(amanda.wilson@alexion.com); ⁴Royal Melbourne Hospital, Melbourne, Australia (jeff.szer@mh.org.au)

Disclosures: PM has received speaker fees from Alexion Pharmaceuticals and served on advisory boards for Alexion Pharmaceuticals, Akari Therapeutics, and Ra Pharma. JS served on advisory boards for Alexion Pharmaceuticals and Ra Pharma and received lecture fees from Alexion Pharmaceuticals. MNY has served on advisory committees and speaker bureaus for Alexion Pharmaceuticals. AW is an employee of Alexion Pharmaceuticals and holds stock in the company.

Author Contributions: MNY, PM, AW and JS contributed equally to the design of the study, interpretation of the data, writing of the manuscript, and approval of the final manuscript. AW contributed to the design of the study, statistical analysis, interpretation of data, writing of the manuscript, and approval of the final manuscript.

Corresponding author:

Mustafa N. Yenerel
Istanbul University, Istanbul Faculty of Medicine
Department of Internal Medicine
Division of Hematology,
Istanbul, Turkey
Email: mnyenerel@gmail.com

Download English Version:

<https://daneshyari.com/en/article/5591449>

Download Persian Version:

<https://daneshyari.com/article/5591449>

[Daneshyari.com](https://daneshyari.com)